Teetering on the brink of a vast patent cliff, Eli Lilly & Co. in mid-September announced a reorganization and cost-cutting initiative designed to reduce costs by $1 billion by the end of 2010. The move is as much about enhancing R&D productivity as creating a leaner organization, according to the company.
Like other Big Pharmas who have reshuffled their businesses in recent years—such as Pfizer Inc. and Merck &...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?